DE602006008456D1 - Amylin und amylinagonisten für die behandlung von psychiatrischen erkrankungen und störungen - Google Patents

Amylin und amylinagonisten für die behandlung von psychiatrischen erkrankungen und störungen

Info

Publication number
DE602006008456D1
DE602006008456D1 DE602006008456T DE602006008456T DE602006008456D1 DE 602006008456 D1 DE602006008456 D1 DE 602006008456D1 DE 602006008456 T DE602006008456 T DE 602006008456T DE 602006008456 T DE602006008456 T DE 602006008456T DE 602006008456 D1 DE602006008456 D1 DE 602006008456D1
Authority
DE
Germany
Prior art keywords
disorders
amylin
lagonists
amyl
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006008456T
Other languages
English (en)
Inventor
Kevin D Laugero
Michael Hanley
Christine M Mack
David G Parkes
Andrew A Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amylin Pharmaceuticals LLC
Original Assignee
Amylin Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amylin Pharmaceuticals LLC filed Critical Amylin Pharmaceuticals LLC
Publication of DE602006008456D1 publication Critical patent/DE602006008456D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE602006008456T 2005-03-31 2006-03-31 Amylin und amylinagonisten für die behandlung von psychiatrischen erkrankungen und störungen Active DE602006008456D1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US66733505P 2005-03-31 2005-03-31
US66668105P 2005-03-31 2005-03-31
US67544105P 2005-04-28 2005-04-28
US76058306P 2006-01-20 2006-01-20
PCT/US2006/012601 WO2006105527A2 (en) 2005-03-31 2006-03-31 Amylin and amylin agonists for treating psychiatric diseases and disorders

Publications (1)

Publication Number Publication Date
DE602006008456D1 true DE602006008456D1 (de) 2009-09-24

Family

ID=37054153

Family Applications (2)

Application Number Title Priority Date Filing Date
DE602006016760T Active DE602006016760D1 (de) 2005-03-31 2006-03-31 Zusammensetzungen und verfahren zur kontrolle, prävention und behandlung von essstörungen
DE602006008456T Active DE602006008456D1 (de) 2005-03-31 2006-03-31 Amylin und amylinagonisten für die behandlung von psychiatrischen erkrankungen und störungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE602006016760T Active DE602006016760D1 (de) 2005-03-31 2006-03-31 Zusammensetzungen und verfahren zur kontrolle, prävention und behandlung von essstörungen

Country Status (17)

Country Link
US (7) US7879794B2 (de)
EP (5) EP1871403B1 (de)
JP (2) JP5415067B2 (de)
KR (3) KR101383493B1 (de)
CN (3) CN101189021B (de)
AT (2) ATE439140T1 (de)
AU (2) AU2006230602B2 (de)
BR (2) BRPI0609595A8 (de)
CA (2) CA2602584A1 (de)
DE (2) DE602006016760D1 (de)
DK (1) DK1888094T3 (de)
EA (1) EA013121B1 (de)
ES (1) ES2330671T3 (de)
IL (1) IL186200A (de)
MX (2) MX2007012236A (de)
NZ (3) NZ561936A (de)
WO (2) WO2006105527A2 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
WO2006083254A1 (en) * 2004-02-11 2006-08-10 Amylin Pharmaceuticals, Inc. Amylin family peptides and methods for making and using them
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
WO2006105527A2 (en) * 2005-03-31 2006-10-05 Amylin Pharmaceuticals, Inc. Amylin and amylin agonists for treating psychiatric diseases and disorders
WO2007014051A2 (en) * 2005-07-22 2007-02-01 Amylin Pharmaceuticals, Inc. Use of amylin and amylin agonists as cardioprotective or myoprotective agents
CN101400698A (zh) 2006-03-15 2009-04-01 诺沃-诺迪斯克有限公司 胰岛淀粉样多肽衍生物
CA2647568A1 (en) * 2006-03-31 2007-10-11 Amylin Pharmaceuticals, Inc. Amylin and amylin agonists for treating psychiatric diseases and disorders
US20090181890A1 (en) * 2006-03-31 2009-07-16 Amylin Pharmaceuticals , Inc. Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders
KR101106510B1 (ko) 2006-05-30 2012-01-20 인타르시아 세라퓨틱스 인코포레이티드 투피스, 내부채널 삼투압 전달 시스템 유동 조절기
MX2009001114A (es) 2006-08-09 2009-02-10 Intarcia Therapeutics Inc Sistemas de suministro osmotico y ensambles de piston.
EP2120985B1 (de) 2007-02-05 2012-06-27 Amylin Pharmaceuticals, Inc. FN-38 Peptide zur Verwendung bei der Behandlung Psychotischer- und Angsterkrankungen
RU2440097C2 (ru) 2007-04-23 2012-01-20 Интарсия Терапьютикс, Инк. Способ лечения диабета ii типа и ожирения, осмотическое устройство для доставки и способ его изготовления
EP2240155B1 (de) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Vorrichtungen, formulierungen und verfahren zur freisetzung mehrerer wirkstoffe
EP2293811A1 (de) * 2008-06-25 2011-03-16 Novo Nordisk A/S Derivatisierte amylin- und lachs-calcitonin-hybridpeptide
EP2340261B1 (de) 2008-10-21 2017-12-20 Novo Nordisk A/S Amylinderivate
SI2373681T1 (sl) 2008-12-10 2017-05-31 Glaxosmithkline Llc Corporation Service Company Farmacevtski sestavki albiglutida
AU2010206614B2 (en) * 2009-01-22 2015-03-26 Keybioscience Ag Treatment for obesity
US20120071401A1 (en) * 2009-04-10 2012-03-22 Amylin Pharamaceuticals, Inc. Amylin agonist compounds for estrogen-deficient mammals
US9901551B2 (en) 2009-04-20 2018-02-27 Ambra Bioscience Llc Chemosensory receptor ligand-based therapies
US8828953B2 (en) * 2009-04-20 2014-09-09 NaZura BioHealth, Inc. Chemosensory receptor ligand-based therapies
AR076341A1 (es) 2009-04-20 2011-06-01 Elcelyx Therapeutics Inc Terapias basadas en ligados de receptores quimiosensoriales. metodo de tratamiento. composicion
SI2462246T1 (en) 2009-09-28 2018-01-31 Intarcia Therapeutics, Inc. Fast-setting and / or cessation of substantially unchanged delivery of the product
US8476227B2 (en) 2010-01-22 2013-07-02 Ethicon Endo-Surgery, Inc. Methods of activating a melanocortin-4 receptor pathway in obese subjects
US9044606B2 (en) 2010-01-22 2015-06-02 Ethicon Endo-Surgery, Inc. Methods and devices for activating brown adipose tissue using electrical energy
WO2011140176A1 (en) 2010-05-04 2011-11-10 Glaxosmithkline Llc Methods for treating or preventing cardiovascular disorders and providing cardiovascular protection
BRPI1005385A2 (pt) 2010-06-28 2016-04-12 Zte Corp sistema de acesso integrado fechados e método de redução para o consumo de energia do mesmo
US9486463B2 (en) 2010-10-19 2016-11-08 Ambra Bioscience Llc Chemosensory receptor ligand-based therapies
BR112013017411B1 (pt) 2011-01-07 2022-03-22 Anji Pharma (Us) Llc Uso de uma composição compreendendo metformina ou um sal da mesma
WO2013103384A1 (en) 2012-01-06 2013-07-11 Elcelyx Therapeutics, Inc. Biguanide compositions and methods of treating metabolic disorders
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
AU2012270366C1 (en) * 2011-06-17 2017-07-13 Hanmi Science Co., Ltd. A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof
EP2807187B1 (de) * 2012-01-26 2017-07-26 Christopher J. Soares Peptidantagonisten aus der calcitonin-cgrp-familie von peptidhormonen und deren verwendung
WO2013158928A2 (en) 2012-04-18 2013-10-24 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
BR102013017626A2 (pt) * 2013-06-14 2015-02-10 Univ Rio De Janeiro Bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, uso de bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, composições farmacêuticas de baixa toxicidade, adjuvante para a prevenção ou tratamento das doenças, medicamento, método de tratamento ou prevenção de doenças.
JP6538682B2 (ja) * 2013-07-30 2019-07-03 ソアレス クリストファー ジェイ． Ｃｇｒｐアゴニストペプチド
AR097701A1 (es) * 2013-09-19 2016-04-13 Zealand Pharma As Análogos de amilina
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10092738B2 (en) 2014-12-29 2018-10-09 Ethicon Llc Methods and devices for inhibiting nerves when activating brown adipose tissue
US10080884B2 (en) 2014-12-29 2018-09-25 Ethicon Llc Methods and devices for activating brown adipose tissue using electrical energy
EP3302354B1 (de) 2015-06-03 2023-10-04 i2o Therapeutics, Inc. Systeme zum einsetzen eines implantats
EP3733694A1 (de) 2016-05-16 2020-11-04 Intarcia Therapeutics, Inc Für den glucagonrezeptor selektive polypeptide und verfahren zu deren verwendung
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
EP3506925B1 (de) 2016-09-02 2023-09-06 Christopher J. Soares Verwendung von cgrp-rezeptor-antagonisten bei der behandlung des glaukoms
MX2019008006A (es) 2017-01-03 2019-08-29 Intarcia Therapeutics Inc Metodos que comprenden la administracion continua de un agonista del receptor de glp-1 y la co-administracion de un farmaco.
US20190382462A1 (en) * 2017-01-13 2019-12-19 Pietro P. Sanna Methods and compositions for treating hpa hyperactivity
EP3628233B1 (de) * 2018-09-28 2021-06-02 Siemens Healthcare GmbH Verfahren und system zur bereitstellung eines dosisreferenzwerts für einen patienten
US11443843B2 (en) 2019-01-04 2022-09-13 International Business Machines Corporation Personal customized guidance for treating patients
CN111700904A (zh) * 2020-07-31 2020-09-25 江南大学 一种利用酰化淀粉定点释放短链脂肪酸的抗抑郁的方法

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0024807B1 (de) 1979-07-28 1983-11-02 Beecham Group Plc Benzocycloheptapyrrolalkansäure und ihre Derivate, Verfahren zu ihrer Herstellung und pharmazeutische Zusammensetzungen, die sie enthalten
US4401593A (en) 1982-02-12 1983-08-30 Armour Pharmaceutical Company Glycine - 8 calcitonin
US4397780A (en) 1982-02-12 1983-08-09 Armour Pharmaceutical Company Leucine22 -calcitonin
US4414149A (en) 1983-03-04 1983-11-08 Armour Pharmaceutical Company Glycine8 -D-arginine24 calcitonin
US4497731A (en) 1983-04-04 1985-02-05 Armour Pharmaceutical Company Glycine 8-des-tyrosine 22 calcitonin
US4495097A (en) 1983-04-04 1985-01-22 Armour Pharmaceutical Company Des-serine2 -glycine8 calcitonin
US4572208A (en) 1983-06-29 1986-02-25 Utah Medical Products, Inc. Metabolic gas monitoring apparatus and method
US4597900A (en) 1983-08-22 1986-07-01 Armour Pharmaceutical Co. Des2 -glycine8 -des22 -calcitonin
US4537716A (en) 1983-12-05 1985-08-27 Armour Pharmaceutical Co. Des-serine2 or des-glycine2 -leucine22 calcitonin
FI78231C (fi) 1984-11-21 1989-07-10 Instrumentarium Oy Maetanordning foer metaboliska storheter anslutbar till en respirator.
US4604238A (en) 1984-12-10 1986-08-05 Armour Pharmaceutical Company Analogs of calcitonin
US4606856A (en) 1985-03-18 1986-08-19 Seyler Jay K [Des-1-amino, 8-glycine]calcitonin
US4652627A (en) 1985-08-16 1987-03-24 Kempe Tomas G Calcitonin analogs with C-terminal D-amino acid substituents
US4687839A (en) 1985-12-23 1987-08-18 Kempe Tomas G Calcitonin gene related peptide analogs with C-terminal D-amino acid substituents
US4697002A (en) 1985-12-23 1987-09-29 Kempe Tomas G Calcitonin gene related peptide analogs with amino acid subdstituents at the penultimate position 36
GB8709871D0 (en) 1987-04-27 1987-06-03 Turner R C Peptides
US5175145A (en) 1988-08-26 1992-12-29 Amylin Pharmaceuticals, Inc. Treatment of diabetes mellitus with amylin agonists
ATE135370T1 (de) 1988-12-22 1996-03-15 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
US5405831A (en) 1989-07-08 1995-04-11 Amylin Pharmaceuticals, Inc. Treatment of bone disorders
US5264372A (en) 1991-03-15 1993-11-23 Amylin Pharmaceuticals, Inc. Receptor-based screening methods for amylin agonists and antagonists
US5234906A (en) 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions
HU222249B1 (hu) 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
SK88793A3 (en) * 1991-11-19 1994-12-07 Amylin Pharmaceuticals Inc Amylin agonising peptides and their using
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US6001364A (en) 1993-05-05 1999-12-14 Gryphon Sciences Hetero-polyoxime compounds and their preparation by parallel assembly
US6174530B1 (en) 1993-05-05 2001-01-16 Gryphon Sciences Homogeneous polyoxime compositions and their preparation by parallel assembly
US5589356A (en) 1993-06-21 1996-12-31 Vanderbilt University Litigation of sidechain unprotected peptides via a masked glycoaldehyde ester and O,N-acyl rearrangement
CZ69596A3 (en) 1993-09-07 1997-06-11 Amylin Pharmaceuticals Inc Application of amylin, amylin agonist, amylin analog agonist or amylin antagonist for preparing a pharmaceutical preparation used for the control of gastrointestinal motility
US5766627A (en) 1993-11-16 1998-06-16 Depotech Multivescular liposomes with controlled release of encapsulated biologically active substances
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6184344B1 (en) 1995-05-04 2001-02-06 The Scripps Research Institute Synthesis of proteins by native chemical ligation
US5739106A (en) * 1995-06-07 1998-04-14 Rink; Timothy J. Appetite regulating compositions
US6013009A (en) 1996-03-12 2000-01-11 Karkanen; Kip Michael Walking/running heart rate monitoring system
US5677279A (en) 1996-12-16 1997-10-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treating pain with amylin or agonists thereof
US6307018B1 (en) 1996-12-24 2001-10-23 The Scripps Research Institute General chemical ligation
CA2277112C (en) 1997-01-07 2008-08-26 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the reduction of food intake
US7312196B2 (en) 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US6410511B2 (en) 1997-01-08 2002-06-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US6309360B1 (en) 1997-03-17 2001-10-30 James R. Mault Respiratory calorimeter
US7101853B2 (en) 1997-05-06 2006-09-05 Amylin Pharmaceuticals, Inc. Method for treating or preventing gastritis using amylin or amylin agonists
US20040022807A1 (en) 1998-06-05 2004-02-05 Duft Bradford J Methods for treating obesity
DE69828287T2 (de) 1997-06-13 2005-12-15 Gryphon Therapeutics, Inc., South San Francisco Festphasige native chemische ligation von ungeschützten oder n-cystein-geschützten peptiden in wässrigen lösungen
EP1091440B1 (de) 1998-05-29 2010-06-02 JGC Catalysts and Chemicals Ltd. Verfahren zur herstellung photoelektrischer zellen
US6087334A (en) 1998-08-21 2000-07-11 Amylin Pharmaceuticals, Inc. Anti-diabetic peptides
CA2351547A1 (en) 1998-08-31 2000-03-09 Gryphon Sciences Lipid matrix-assisted chemical ligation and synthesis of membrane polypeptides
US6194006B1 (en) 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
TW514510B (en) 1999-06-11 2002-12-21 Tanita Seisakusho Kk Method and apparatus for measuring distribution of body fat
US6468222B1 (en) 1999-08-02 2002-10-22 Healthetech, Inc. Metabolic calorimeter employing respiratory gas analysis
US6530886B1 (en) 1999-10-08 2003-03-11 Tanita Corporation Method and apparatus for measuring subcutaneous fat using ultrasonic wave
US6264987B1 (en) 2000-05-19 2001-07-24 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
TW515705B (en) 2000-05-31 2003-01-01 Yamato Scale Co Ltd Visceral fat meter
US6296842B1 (en) 2000-08-10 2001-10-02 Alkermes Controlled Therapeutics, Inc. Process for the preparation of polymer-based sustained release compositions
US7118737B2 (en) 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
AU2001278905B2 (en) 2000-09-08 2004-12-16 Gryphon Therapeutics, Inc. Synthetic erythropoiesis stimulating proteins
US6475158B1 (en) 2000-10-24 2002-11-05 Korr Medical Technologies, Inc. Calorimetry systems and methods
GB0113657D0 (en) 2001-06-05 2001-07-25 Geneprot Inc Improved native chemical ligation with three or more components
FR2827599A1 (fr) 2001-07-20 2003-01-24 Neuro3D Composes derives de quinoleine et quinoxaline,preparation et utilisations
US20040138412A1 (en) 2001-09-07 2004-07-15 Paolo Botti Extended native chemical ligation
JP4399627B2 (ja) 2001-11-14 2010-01-20 ジェネプロット インコーポレーティッド ３つまたはそれ以上の成分による化学ペプチド連結
EP1474164B1 (de) 2002-01-08 2008-10-29 Amylin Pharmaceuticals, Inc. Verwendung von amylin, amylinanaloga und amylin derivaten zur behandlung von dyslipidämie und hypertriglyceridämie
AR040126A1 (es) * 2002-05-29 2005-03-16 Glaxo Group Ltd Compuesto de fenilsulfonilo, composicion farmaceutica que lo comprende y su uso para la elaboracion de un medicamento
JP4327718B2 (ja) 2002-06-10 2009-09-09 ジーンプロット インコーポレーティッド オリゴペプチドの化学連結における酸性ｃ末端アミノ酸についてのカルボキシ保護ストラテジー
AU2003298739A1 (en) 2002-11-26 2004-06-18 The Board Of Trustees Of The Leland Stanford Junior University Intermedin and its uses
EP1616021A4 (de) 2002-12-30 2006-08-30 Gryphon Therapeutics Inc Multiplex-polymerligation
US20040197287A1 (en) * 2003-04-04 2004-10-07 The Procter & Gamble Company Personal care composition containing an antidandruff component and a nonionic surfactant
WO2004105685A2 (en) 2003-05-22 2004-12-09 Gryphon Therapeutics, Inc. Displaceable linker solid phase chemical ligation
WO2006083254A1 (en) 2004-02-11 2006-08-10 Amylin Pharmaceuticals, Inc. Amylin family peptides and methods for making and using them
US7399744B2 (en) 2004-03-04 2008-07-15 Amylin Pharmaceuticals, Inc. Methods for affecting body composition
CN101035806A (zh) 2004-10-08 2007-09-12 安米林药品公司 新的糊精家族多肽－6（afp－6）类似物和制备和使用它们的方法
WO2006105527A2 (en) 2005-03-31 2006-10-05 Amylin Pharmaceuticals, Inc. Amylin and amylin agonists for treating psychiatric diseases and disorders

Also Published As

Publication number Publication date
US20130225485A1 (en) 2013-08-29
WO2006105527A2 (en) 2006-10-05
NZ578298A (en) 2010-07-30
BRPI0609595A2 (pt) 2010-04-20
KR20130122983A (ko) 2013-11-11
JP2008534606A (ja) 2008-08-28
EA013121B1 (ru) 2010-02-26
US8389477B2 (en) 2013-03-05
ATE480255T1 (de) 2010-09-15
KR20070119718A (ko) 2007-12-20
DK1888094T3 (da) 2009-11-09
EP2248527A2 (de) 2010-11-10
EP2248527A3 (de) 2013-04-03
BRPI0609595A8 (pt) 2018-05-15
US8278267B2 (en) 2012-10-02
JP2008534627A (ja) 2008-08-28
WO2006105345A9 (en) 2007-03-22
EP2258382A2 (de) 2010-12-08
NZ561936A (en) 2009-07-31
CN101189021A (zh) 2008-05-28
EP1888094B1 (de) 2009-08-12
CN102343084A (zh) 2012-02-08
IL186200A0 (en) 2008-01-20
US7671023B2 (en) 2010-03-02
CA2602584A1 (en) 2006-10-05
US7879794B2 (en) 2011-02-01
WO2006105527A3 (en) 2007-01-11
WO2006105345A2 (en) 2006-10-05
ES2330671T3 (es) 2009-12-14
US20100125054A1 (en) 2010-05-20
IL186200A (en) 2013-09-30
AU2006230602B2 (en) 2010-07-15
EP2258382A3 (de) 2014-05-14
US20110288028A1 (en) 2011-11-24
AU2006230420B2 (en) 2011-11-24
JP5415067B2 (ja) 2014-02-12
CA2602261A1 (en) 2006-10-05
KR20080003849A (ko) 2008-01-08
CN101189021B (zh) 2011-12-14
EP1871403A2 (de) 2008-01-02
BRPI0606466A2 (pt) 2009-06-30
EA200702126A1 (ru) 2008-04-28
EP2135617A2 (de) 2009-12-23
MX2007012237A (es) 2007-12-07
US20090062193A1 (en) 2009-03-05
EP2135617A3 (de) 2013-09-18
WO2006105345A3 (en) 2007-02-01
ATE439140T1 (de) 2009-08-15
AU2006230602A1 (en) 2006-10-05
EP1888094A2 (de) 2008-02-20
DE602006016760D1 (de) 2010-10-21
US20080287355A1 (en) 2008-11-20
KR101383493B1 (ko) 2014-04-11
US20110263491A1 (en) 2011-10-27
CN101415435A (zh) 2009-04-22
MX2007012236A (es) 2007-12-06
NZ578299A (en) 2010-03-26
AU2006230420A1 (en) 2006-10-05
US20130184213A1 (en) 2013-07-18
JP5114381B2 (ja) 2013-01-09
EP1871403B1 (de) 2010-09-08

Similar Documents

Publication Publication Date Title
DE602006008456D1 (de) Amylin und amylinagonisten für die behandlung von psychiatrischen erkrankungen und störungen
NL301145I2 (nl) Tirbanibulin
ATE528002T1 (de) Pyridoncarboxamidderivate zur behandlung hyperproliferativer und angiogenese-vermittelter leiden
GB2463833A (en) Methods and compositions for the treatment of neurological disorders
DE602005013116D1 (de) Pyridin-verbindungen für die behandlung von prostaglandin-vermittelten krankheiten
ATE453642T1 (de) Substituierte phenylaminopyrimidine
WO2007022506A3 (en) Methods and compositions for treating neurological disease
BRPI0512856A (pt) métodos e reagentes para o tratamento de distúrbios metabólicos
ATE416177T1 (de) Hetaryloxy-substituierte phenylaminopyrimidine als rho-kinasehemmer
ATE433966T1 (de) Methylendipiperidinderivate
NO20074943L (no) Roflumilast for behandlingen av diabetes mellitus
EA201001695A1 (ru) Применение эпотилона d для лечения заболеваний, связанных с тау-белком
MX2007010484A (es) Moleculas y metodos para usarlas para tratar enfermedades asociadas con mcp-1/ccr2.
ATE518846T1 (de) 2-aminooxazolderivate als für die behandlung von schmerzen geeignete trpvl-antagonisten
ATE422498T1 (de) Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems
ATE410166T1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin- derivate zur behandlung von unfruchtbarkeit
DE602005015697D1 (de) Te zur behandlung von alzheimer-krankheit
NO20081835L (no) Behandlingsmetoder ved bruk av oksytocin receptoragonister
HK1102626A1 (en) Compositions and methods for the treatment and prevention of hyperproliferative diseases
DE602006012313D1 (de) Kombination aus pyrimidylaminobenzamid-verbindungen und imatinib zur behandlung oder verhinderung proliferativer erkrankungen
ZA200609220B (en) Method of treating dry eye disorders and uveitis
CY1116166T1 (el) Νεα μεθοδος για την αντιμετωπιση λοιμωξεων απο η.pylori
DE602004026597D1 (de) Behandlung von alzheimer-krankheit und verwandten zuständen
WO2006065968A8 (en) The uses of estrogen beta agonists to treat cognitive diseases
ATE446757T1 (de) 1-ä2h-1-benzopyran-2-one-8-ylü- piperazinderivative zur behandlung von bewegungsstörungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition